Amgen's AMG 416 succeeds in second Phase III study
This article was originally published in Scrip
Executive Summary
Amgen reported after the stock market closed on 18 August that the company's Sensipar (cinacalcet) franchise extender AMG 416 (velcalcetide) succeeded in a second placebo-controlled Phase III clinical trial for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are receiving hemodialysis.